Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Next Previous
Trial Profile

A Phase 1 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemsidomide (Primary) ; Dexamethasone (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors C4 Therapeutics

Most Recent Events

  • 12 May 2026 According to a C4 Therapeutics media release, data from the Phase 1 trial evaluating cemsidomide in combination with dexamethasone in RRMM was accepted as a poster presentation at the European Hematology Annual (EHA) Congress taking place from June 11-June 14, 2026, in Stockholm, Sweden.
  • 25 Mar 2026 Planned End Date changed from 31 Mar 2026 to 31 Dec 2026.
  • 25 Mar 2026 Planned primary completion date changed from 31 Dec 2025 to 30 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top